Lumateperone deuterated - Intra-Cellular Therapies
Alternative Names: ITI 1284; ITI-1284 ODT-SLLatest Information Update: 14 Aug 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Intra-Cellular Therapies
- Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Organic deuterium compounds; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
- Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Agitation; Generalised anxiety disorder; Psychotic disorders
- No development reported Behavioural disorders; Dementia; Depressive disorders
Most Recent Events
- 07 Aug 2024 Intra-Cellular Therapies plans a phase II trial for Generalized anxiety disorder (GAD) (Monotherapy) in 2024
- 06 Aug 2024 Phase-II clinical trials in Psychotic disorders in USA (Sublingual) (NCT06540833)
- 05 Aug 2024 Phase-II clinical trials in Generalised anxiety disorder (Adjunctive treatment) (Sublingual) (NCT06480383)